Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 674 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert A. Fuller sold 674 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $31.44, for a total transaction of $21,190.56. The sale was disclosed in a document filed with the SEC, which is available at this link.

USANA Health Sciences Price Performance

Shares of NYSE USNA traded down $1.34 during mid-day trading on Friday, hitting $29.04. The company's stock had a trading volume of 229,896 shares, compared to its average volume of 101,852. The stock has a market cap of $553.41 million, a price-to-earnings ratio of 10.26, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The company's fifty day simple moving average is $32.67 and its 200-day simple moving average is $36.01.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. On average, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have commented on USNA. DA Davidson decreased their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of USNA. KBC Group NV boosted its stake in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company's stock valued at $40,000 after purchasing an additional 519 shares during the last quarter. Royce & Associates LP raised its position in shares of USANA Health Sciences by 22.2% in the 3rd quarter. Royce & Associates LP now owns 33,143 shares of the company's stock valued at $1,257,000 after acquiring an additional 6,031 shares during the period. Quest Partners LLC acquired a new stake in shares of USANA Health Sciences in the 3rd quarter valued at approximately $250,000. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 7.5% in the 3rd quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company's stock valued at $39,801,000 after acquiring an additional 72,977 shares during the period. Finally, Pacer Advisors Inc. raised its position in shares of USANA Health Sciences by 16.5% in the 3rd quarter. Pacer Advisors Inc. now owns 544,256 shares of the company's stock valued at $20,638,000 after acquiring an additional 76,904 shares during the period. Institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.